此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Mind-Body Sexual Well-Being Program for Female GI Cancer Survivors

2026年9月2日 更新者:Lucy Finkelstein-Fox, PhD、Massachusetts General Hospital

Refining a Mind-Body Sexual Well-Being Program for Female GI Cancer Survivors

This record describes two distinct study phases: 1) A small open pilot trial including up to 10 participants, intended to generate descriptive feedback on regarding perceived benefits and areas for improvement for a group-based mind-body sexual well-being program for women treated for colorectal and anal cancers and 2) A pilot randomized controlled trial (RCT) including up to 100 participants, intended to provide information about feasibility, acceptability, and preliminary efficacy of the group-based mind-body sexual well-being program compared to enhanced usual care control (EUCC).

Given the early-stage, open-pilot nature of the first study phase, which is not intended to produce interpretable results for feasibility, acceptability, or efficacy, this record will only report results from the second study phase (pilot RCT).

研究概览

详细说明

The primary objective of this protocol is to iteratively refine and pilot test a novel mind-body sexual well-being intervention that investigators have developed in previous research (DF-HCC protocols #22-586, #24-009, and #24-281). This protocol will include 2 study phases, including a small open pilot trial (Phase 1) and a subsequent larger randomized pilot trial (Phase 2). This protocol builds on previous work conducted by the investigators to develop a 6-week, group-based, mind-body sexual well-being program for female survivors of colorectal and anal cancer.

For Phase 1 (Open Pilot Trial), participants will complete electronic informed consent (including HIPAA authorization for access to relevant medical information in the EHR) prior to initiation of study procedures. Participants will then be invited to attend approximately 6 weeks of group-based sessions, lasting for approximately 90 minutes and including content related to mind-body medicine and complementary medical resources relevant to survivors' sexual well-being. To help investigators further refine the sexual well-being program for the next phase of the study, investigators will ask participants to complete brief (approximately 30 minute) survey batteries via REDCap at baseline and after the 6-session program, including assessments of intervention feasibility and acceptability as well as relevant psychosocial outcomes.

For Phase 2 (Randomized Pilot Trial), participants will complete electronic informed consent (including HIPAA authorization for access to relevant medical information in the EHR) prior to initiation of study procedures. Participants will then be randomized into groups (mind-body intervention groups vs. enhanced usual care control (EUCC)).

Participants randomized to EUCC will not receive any components of the mind-body group intervention. As part of this condition, participants will receive the current standard of care for patients at MGH and additionally receive a standard resource sheet to ensure that all participants receive a basic level of information specific to sexuality in cancer survivorship. As part of routine study assessments, investigators will measure EUCC participants' level of engagement with the Sexual Health Clinic and other supportive resources.

Participants in the mind-body group intervention arm will receive the same educational information about available sexual health resources as the EUCC participants to ensure equal familiarity with supportive resources within and outside of MGH. Participants randomized to receive the mind-body group intervention will also participate in a similar approximately 6-week group-based mind-body sexual well-being program as is described for Aim 1.

Just as for Aim 1, to inform ongoing intervention refinement, investigators will ask all participants to complete brief (approximately 30 minute) survey batteries via REDCap at baseline and after the 6-session program, including items related to feasibility, acceptability, and relevant psychosocial outcomes. Investigators will only randomize participants after receiving a completed baseline survey; participants who do not complete the baseline survey will not be counted towards the total number enrolled in the study. To capture symptom change over a longer period, investigators will also ask participants to complete survey batteries at 3-month post-intervention follow-up.

Approximately 20 participants randomized to receive the novel mind-body group study intervention will also be invited to complete a brief qualitative exit interview with a member of the study team, regarding perceived benefit of the intervention as well as and strengths and weaknesses of program content and delivery format to inform ongoing intervention refinement.

研究类型

介入性

注册 (估计的)

100

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • Mass General Brigham Cancer Institute
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Female sex
  2. Able to speak and read English
  3. Aged 18 or older
  4. Receive any cancer care at any MGH-CC site (Boston, Waltham, Danvers, Newton Wellesley Hospital)
  5. Completed initial active treatment (i.e., surgery, radiation, chemotherapy) for colorectal or anal cancer approximately 3 months or more prior to enrollment (for curvivors/individuals treated for cancer with curative intent) or were diagnosed at least 3 months ago (for metavivors/individuals living with chronic cancer)
  6. Verbally endorse experiencing distressing changes to sexual health or intimate relationships, including changes that may be related to cancer diagnosis and treatment
  7. Access to an internet-connected device with video

Exclusion Criteria:

  • Active psychiatric or cognitive comorbidity that prohibits the capacity to provide informed consent as determined by the study PI, a licensed psychologist, in collaboration with the patient's medical team
  • Adults unable to complete study procedures in English
  • Participated in an earlier phase of the study (DF-HCC protocols #22-586, #24-009, #24-281).

In addition, individuals who participate in Phase 1 of this protocol (open pilot trial) will not be eligible to participate in Phase 2 (pilot RCT). Investigators will not enroll the following special populations: adults unable to consent, individuals who are not yet adults (i.e., < age 18), pregnant women, and prisoners.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Mind-Body Sexual Well-Being Group Intervention

Participants in the mind-body sexual well-being group intervention arm will participate in 6 weekly group sessions, delivered via videoconferencing, following enrollment. Group sessions will include content related to mind-body medicine (e.g., relaxation, mindfulness, self-compassion) applied to sexual well-being as well as educational information related to women's sexual well-being in cancer survivorship. Before and after completing the group program, participants will also complete brief self-assessment questionnaires.

Participants in the mind-body group intervention arm will also receive the same educational information about available sexual health resources as the EUCC participants, to ensure equal familiarity with high-quality educational and supportive resources related to women's sexual well-being and cancer.

在大约 6 周的时间内,每周与研究干预专家和最多 9 名其他女性癌症幸存者举行虚拟小组会议。 小组计划包括与应对身体健康变化、管理与性健康相关的社会因素以及管理与性健康变化相关的想法和感受相关的主题。
有源比较器:Enhanced Usual Care Control (EUCC)
Participants randomized to EUCC will not receive any components of the mind-body group intervention. After randomization, the study CRC will offer participants a handout listing information about several high-quality sexual health resources currently available to them.
Participants randomized to EUCC will not receive any components of the mind-body group intervention. After randomization, the study CRC will offer participants a handout listing information about sexual health resources currently available to them that they may choose to access. Participants in the EUCC condition will also have the option of seeking care through the cancer center's local sexual health program, as is the current standard of care.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Acceptability of Intervention
大体时间:Approximately 6 weeks following group program start
To establish acceptability, we will examine the % of participants scoring at or above the scale midpoint on the CSQ-8 (>/= 70% as criteria for acceptability).
Approximately 6 weeks following group program start
Feasibility of Intervention
大体时间:Approximately 6 weeks after the final 6-week group program begins
To explore feasibility, investigators will use descriptive statistics (i.e., frequency and percentages) to evaluate the proportion of enrolled participants who completed at least 66%, or 4/6, of the scheduled intervention sessions (>/= 70% as our cutoff criteria for feasibility).
Approximately 6 weeks after the final 6-week group program begins

其他结果措施

结果测量
措施说明
大体时间
Sexual Satisfaction
大体时间:Approximately 6 weeks following group program start
A key exploratory aim of the proposed research is to determine the strength of within-group changes in satisfaction with sex life (subscale of the PROMIS-SexFS) for participants randomized to both groups, which will inform future trial design for a larger efficacy study.
Approximately 6 weeks following group program start

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Lucy Finkelstein-Fox, PhD、Massachusetts General Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2029年6月1日

研究完成 (估计的)

2029年6月1日

研究注册日期

首次提交

2026年8月25日

首先提交符合 QC 标准的

2026年8月25日

首次发布 (实际的)

2026年8月31日

研究记录更新

最后更新发布 (实际的)

2026年9月8日

上次提交的符合 QC 标准的更新

2026年9月2日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: lfinkelsteinfox@mgh.harvard.edu. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD 共享时间框架

Data can be shared no earlier than 1 year following the date of publication

IPD 共享访问标准

Contact the Partners Innovations team

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅